Skip to main content
Clinical Trials/NCT06488807
NCT06488807RecruitingNot Applicable

Treatment of Perioperative Neurocognitive Disorders With Olfactory Enrichment: Study Protocol for a Randomized Controlled Trial

Shanghai 10th People's Hospital1 site in 1 country686 target enrollmentStarted: April 7, 2025Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
686
Locations
1
Primary Endpoint
Incidence of postoperative delirium

Study Overview

Brief Summary

Perioperative neurocognitive disorder (PND) is one of the most common postoperative complications among elderly patients. However, the mechanism and targeted intervention of PND remains unclear. Our previous clinical studies demonstrated the association between olfactory impairment and PND. Moreover, our translational studies showed that anesthesia/surgery induced olfactory impairment and caused cognitive impairment in mice and olfactory enrichment could prevent the anesthesia/surgery-induced cognitive impairment. However, there was no clinical investigation to determine whether olfactory enrichment can mitigate PND in elderly patients. Therefore, we propose determining whether olfactory enrichment can prevent and/or treat PND in elderly patients.

Detailed Description

The study will be a double-blinded, randomized controlled trial. Participants (65 years old or older) undergoing scheduled orthopaedic surgery (≥2 hours, under general anesthesia) will be randomized to either olfactory enrichment group or sham group. Participants in olfactory enrichment group will receive olfactory enrichment with a dispenser twice sessions per day on preoperative day 1-3 and postoperative day 1-3 (30 min per session, 4 odors for each session) while participants in sham group will be equipped with the same pattern except that water will be used in the dispenser. Participants will be assessed twice daily by a research assistant blinded to allocation. The primary outcome will be the incidence of postoperative delirium measured by the Confusion Assessment Method on postoperative days 1, 2 and 3. The secondary outcomes will be the severity of postoperative delirium, cognitive function, plasma Tau-PT217 level, and olfactory function.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Care Provider, Outcomes Assessor)

Eligibility Criteria

Ages
65 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥65 years old.
  • Having a scheduled surgery (≥2 hours, general anesthesia) (e.g., total hip replacement, toal knee replacement, open reduction and internal fixation of hip and lumbar spine).
  • Being able to complete neuropsychological tests, 3D-CAM and CAM-S.
  • Chinese Mandarin as their native language.
  • Edmonton frailty scale (EFS) score ≥ 6.

Exclusion Criteria

  • Having delirium, assessed by 3D-CAM, before surgery.
  • Having a brain tumour, stroke or mental disorders (eg, major depressive disorder or dementia).
  • Participating in other clinical studies at the time of screening.
  • Unwillingness to comply with the protocol or procedures.

Outcomes

Primary Outcomes

Incidence of postoperative delirium

Time Frame: at baseline and postoperative day 1 to 3

The presence of postoperative delirium will be defined according to 3D-CAM, which includes four entries: acute onset and fluctuating course, inattention, disorganized thinking and altered level of consciousness. To diagnose delirium, both the first and second criteria have to be present plus the third and/or fourth criteria. Every participant will be assessed twice daily after anesthesia/surgery from postoperative day 1 to postoperative day 3, with the first assessment between 8:00 and 10:00. The second assessment will be between 15:00 and 17:00.

Secondary Outcomes

  • Incidence of delayed neurocognitive recovery and postoperative neurocognitive disorder(at baseline, on 21 days and 6 months after anesthesia/surgery)

Investigators

Sponsor
Shanghai 10th People's Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Yuan Shen, MD, PhD

Director

Shanghai 10th People's Hospital

Study Sites (1)

Loading locations...

Similar Trials